MedTrace Logo

Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy

NCT06429020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1089

Last updated 2024-05-24

No results posted yet for this study

Summary

This study aimed to provide vast clinical information to facilitate breast sonographic examination for participants who underwent recent SARS-CoV-2 vaccination.

Among different SARS-CoV-2 vaccines in the Asian Taiwanese population, reactive axillary lymphadenopathy was investigated through breast sonographic findings and clinical data analysis. The sample included participants with recent vaccinations by different brands approved in Taiwan.

Conditions

  • Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population

Interventions

BIOLOGICAL

the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.

record the condition of vaccination

Sponsors & Collaborators

  • Chimei Medical Center

    lead OTHER

Principal Investigators

  • Pin Chi Huang · ChiMei Medical Center, Taiwan, R.O.C.

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06429020 on ClinicalTrials.gov